Blog, News, Companies, blood glucose meters, oral, Nasal, transdermal, insulin,type 2, pancreatic islet cells, Macular Edema, Ulcers, continuous glucose monitoring, HbA1c, hemoglobin A1C, oral anti-diabetic agent, data management system, Hypoglycemia, glucagon, therapeutic vaccine, peripheral neuropathy, Neuropathic pain, diabetes mellitus, type 1, foot ulcers, test strip, glycemic control, nephropathy, resistant, sensitizers, foot infections, sensor, retinopathy, non-invasive monitor...
Jan 07, 2008 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that initial clinical study results for APD668, an oral drug candidate discovered by Arena and being investigated for the treatment of type 2 diabetes under a partnership with 
Ortho-McNeil Pharmaceutical, Inc., suggest that Glucose-Dependent Insulinotropic Receptors, or GDIRs, may improve glucose control in patients with type 2 diabetes... Arena's Press Release-
